0000899243-19-023329.txt : 20190911
0000899243-19-023329.hdr.sgml : 20190911
20190911173906
ACCESSION NUMBER: 0000899243-19-023329
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190909
FILED AS OF DATE: 20190911
DATE AS OF CHANGE: 20190911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DRACHMAN JONATHAN G
CENTRAL INDEX KEY: 0001588467
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 191089120
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 401 TERRY AVENUE NORTH
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-732-2133
MAIL ADDRESS:
STREET 1: 401 TERRY AVENUE NORTH
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
DATE OF NAME CHANGE: 20140128
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-09
0
0001404644
Neoleukin Therapeutics, Inc.
NLTX
0001588467
DRACHMAN JONATHAN G
C/O NEOLEUKIN THERAPEUTICS, INC.
401 TERRY AVENUE NORTH
SEATTLE
WA
98109
1
1
0
0
See Remarks
Common Stock
2019-09-09
4
P
0
76822
2.845
A
411250
D
Common Stock
2019-09-10
4
P
0
36742
3.0834
A
447992
D
Common Stock
2019-09-11
4
P
0
136436
3.2975
A
584428
D
Series A Preferred Stock
7428
D
Represents the weighted average purchase price. The lowest price at which shares were purchased was $2.82 and the highest price at which shares were purchased was $2.85. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
Represents the weighted average purchase price. The lowest price at which shares were purchased was $3.00 and the highest price at which shares were purchased was $3.10.
Represents the weighted average purchase price. The lowest price at which shares were purchased was $3.06 and the highest price at which shares were purchased was $3.50.
Each share of Series A Convertible Preferred Stock will become convertible into 100 shares of the Issuer's Common Stock, subject to and contingent upon the approval of the Issuer's stockholders in accordance with the Nasdaq Stock Market Rules. Under the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated August 5, 2019, among the Issuer, Aquinox Pharmaceuticals, Inc. and Apollo Sub, Inc., the Issuer has agreed to use commercially reasonable efforts to call and hold a meeting of the Issuer's stockholders to obtain the requisite approval for the conversion of the Series A Convertible Preferred Stock into shares of Common Stock, for purposes of the Nasdaq Stock Market Rules, as soon as practicable and in any event no later than 100 days after the date of the Merger Agreement.
President and Chief Executive Officer
/s/ Kamran Alam, Attorney-in-fact for Jonathan G. Drachman
2019-09-11